Oral Delivery of Taxanes

BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTER

1993 • 3,515 citations

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

1976 • 3,228 citations

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.

1987 • 2,788 citations

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs

1994 • 2,255 citations

THE BIOCHEMISTRY OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG RESISTANCE

1989 • 2,060 citations

Paclitaxel (Taxol)

1995 • 1,747 citations

Expression of a multidrug-resistance gene in human tumors and tissues.

1987 • 1,547 citations

Hypersensitivity reactions from taxol.

1990 • 1,153 citations

Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins

1997 • 934 citations

Patient preferences for oral versus intravenous palliative chemotherapy.

1997 • 922 citations

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine

1997 • 871 citations

Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.

1995 • 550 citations

Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.

1999 • 330 citations

Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.

1993 • 311 citations

Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.

1996 • 304 citations

Oral chemotherapy: rationale and future directions.

1998 • 296 citations

Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme.

1994 • 282 citations

Taxanes: A New Class of Antitumor Agents

1995 • 276 citations

Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.

1997 • 272 citations

Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.

1998 • 253 citations

Pharmacology and Toxicology of Cremophor EL Diluent

1994 • 227 citations

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients

1999 • 206 citations

Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.

1999 • 202 citations

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833

1997 • 201 citations

Coadministration of Cyclosporine Strongly Enhances the Oral Bioavailability of Docetaxel

2001 • 200 citations

Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.

1997 • 181 citations

Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals

1993 • 171 citations

Bioavailability of low-dose oral etoposide.

1993 • 147 citations

Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A.

1998 • 141 citations

Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein

1998 • 141 citations

The Functional Role of P-Glycoprotein in the Blood–Brain Barrier

1997 • 138 citations

Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice

1994 • 132 citations

THE PHARMACOLOGICAL ROLE OF P-GLYCOPROTEIN IN THE INTESTINAL EPITHELIUM

1998 • 130 citations

Tissue distribution, metabolism and excretion of paclitaxel in mice

1996 • 123 citations

Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase.

1993 • 120 citations

Human (MDR1) and Mouse (mdr1,mdr3) P-glycoproteins Can Be Distinguished by Their Respective Drug Resistance Profiles and Sensitivity to Modulators

1995 • 109 citations

What have we learnt thus far from mice with disrupted P-glycoprotein genes?

1996 • 109 citations

A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration

1995 • 100 citations

Phase I and Pharmacokinetic Study of Oral Paclitaxel

2000 • 99 citations

Multidrug resistance of cancer cells

1996 • 89 citations

Clinical pharmacology of anticancer agents in relation to formulations and administration routes

1999 • 59 citations

Hypersensitivity Reactions to the Taxanes Paclitaxel and Docetaxel

1997 • 53 citations

The Oral Route for the Administration of Cytotoxic Drugs: Strategies to Increase the Efficiency and Consistency of Drug Delivery

2000 • 51 citations

Treatment of Non-Small-Cell Lung Cancer With Prolonged Oral Etoposide

1998 • 46 citations

A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A

2001 • 43 citations

Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration

2000 • 27 citations

[Pharmacokinetics of paclitaxel in experimental animals. Part 1. Blood level].

1994 • 10 citations

Deleted Work

1955 • 0 citations